MED - Medifast Inc Stock Price, Fair Value and News

25.48USD+0.12 (+0.47%)Delayed as of 16 May 2024, 09:46 am ET

Market Summary

USD25.48+0.12

Delayedas of 16 May 2024, 09:46 am

0.47%

MED Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)

MED Stock Price

View Fullscreen

MED RSI Chart

MED Valuation

Market Cap

277.4M

Price/Earnings (Trailing)

4.09

Price/Sales (Trailing)

0.31

EV/EBITDA

1.79

Price/Free Cashflow

3.28

MED Price/Sales (Trailing)

MED Profitability

Operating Margin

73.15%

EBT Margin

9.70%

Return on Equity

32.12%

Return on Assets

22.38%

Free Cashflow Yield

30.53%

MED Fundamentals

MED Revenue

Revenue (TTM)

897.8M

Rev. Growth (Yr)

-49.93%

Rev. Growth (Qtr)

-8.52%

MED Earnings

Earnings (TTM)

67.8M

Earnings Growth (Yr)

-79.19%

Earnings Growth (Qtr)

37.78%

Breaking Down MED Revenue

52 Week Range

25.36109.52

(Low)(High)

Last 7 days

1.4%

Last 30 days

-19.3%

Last 90 days

-50.8%

Trailing 12 Months

-71.9%

How does MED drawdown profile look like?

MED Financial Health

Current Ratio

2.84

MED Investor Care

Dividend Yield

13.01%

Dividend/Share (TTM)

3.3

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

6.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	897.8M	0	0	0
2023	1.5B	1.4B	1.2B	1.1B
2022	1.6B	1.7B	1.6B	1.6B
2021	1.1B	1.3B	1.4B	1.5B
2020	726.3M	759.2M	840.6M	934.8M
2019	568.3M	638.1M	688.9M	713.7M
2018	329.5M	371.1M	433.2M	501.0M
2017	272.8M	277.4M	286.0M	301.6M
2016	271.8M	270.7M	273.4M	274.5M
2015	279.4M	276.8M	273.8M	272.8M
2014	307.2M	284.9M	267.4M	285.3M
2013	325.7M	329.2M	324.7M	324.1M
2012	312.8M	328.1M	343.0M	318.6M
2011	271.3M	282.9M	291.6M	298.2M
2010	0	199.0M	228.3M	257.6M
2009	0	0	0	169.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Medifast Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	mackenzie jonathan barrett	sold (taxes)	-4,905	36.61	-134	vp, finance & cao
Mar 15, 2024	maloney james p.	sold (taxes)	-22,551	36.61	-616	chief financial officer
Mar 15, 2024	chard daniel r	sold (taxes)	-124,803	36.61	-3,409	chairman & ceo
Mar 13, 2024	maloney james p.	acquired	-	-	8,718	chief financial officer
Mar 13, 2024	mackenzie jonathan barrett	acquired	-	-	2,565	vp, finance & cao
Mar 13, 2024	chard daniel r	acquired	-	-	45,087	chairman & ceo
Mar 08, 2024	schlackman scott	sold	-159,866	39.444	-4,053	-
Mar 08, 2024	schlackman scott	acquired	35,984	27.68	1,300	-
Feb 14, 2024	chard daniel r	sold (taxes)	-288,212	52.68	-5,471	chairman & ceo
Feb 14, 2024	chard daniel r	acquired	-	-	16,486	chairman & ceo

Which funds bought or sold MED recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Mariner, LLC	new	-	475,924	475,924	-%
May 15, 2024	Lombard Odier Asset Management (USA) Corp	new	-	553,647	553,647	0.01%
May 15, 2024	Cresset Asset Management, LLC	added	108	199,384	1,265,370	0.01%
May 15, 2024	Steward Partners Investment Advisory, LLC	sold off	-100	-22,250	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	95.98	296,402	2,825,490	-%
May 15, 2024	Walleye Capital LLC	new	-	1,404,430	1,404,430	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	new	-	919,412	919,412	0.16%
May 15, 2024	SYSTEMATIC FINANCIAL MANAGEMENT LP	sold off	-100	-1,730,570	-	-%
May 15, 2024	Summit Street Capital Management, LLC	unchanged	-	-852,550	1,130,440	0.43%
May 15, 2024	Quarry LP	new	-	14,753	14,753	-%

Are Funds Buying or Selling MED?

Are funds buying MED calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MED

No. of Funds

Unveiling Medifast Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	6.96%	757,610	SC 13G/A
Feb 13, 2024	vanguard group inc	15.49%	1,686,957	SC 13G/A
Jan 22, 2024	blackrock inc.	16.6%	1,805,021	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.78%	632,110	SC 13G/A
Feb 09, 2023	vanguard group inc	15.35%	1,676,883	SC 13G/A
Jan 26, 2023	blackrock inc.	16.9%	1,847,773	SC 13G/A
Jan 20, 2023	blackrock inc.	16.9%	1,847,773	SC 13G/A
Feb 11, 2022	renaissance technologies llc	6.87%	797,610	SC 13G/A
Feb 10, 2022	vanguard group inc	12.91%	1,499,306	SC 13G/A
Jan 27, 2022	blackrock inc.	17.2%	1,995,911	SC 13G/A

Recent SEC filings of Medifast Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	ARS	ARS
Apr 29, 2024	10-Q	Quarterly Report
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Medifast Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ROL	22.9B	3.2B	9.03%	12.41%	51.8	7.22	14.49%	15.15%
SCI	10.2B	4.1B	-	7.32%	19.48	2.48	2.27%	6.78%
MID-CAP
BFAM	6.7B	2.5B	8.29%	34.11%	80.35	2.68	17.68%	19.79%
FTDR	2.8B	1.8B	21.15%	16.04%	15.55	1.59	6.73%	101.10%
MCW	2.5B	940.3M	17.60%	-13.79%	32.7	2.63	6.48%	-23.25%
SMALL-CAP
CSV	401.0M	390.5M	10.05%	-2.72%	12.71	1.03	6.25%	-6.74%
MED	277.4M	897.8M	-19.30%	-71.85%	4.09	0.31	-41.32%	-52.20%
WW	151.4M	854.2M	11.05%	-73.29%	-0.44	0.18	-13.19%	7.03%
RGS	14.8M	209.3M	9.32%	-68.41%	-2.99	0.07	-14.10%	89.07%

Medifast Inc News

Latest updates

Medifast Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-8.5%	175	191	236	296	349	337	390	453	418	378	413	394	341	265	271	220	178	171	190	187	166
Cost Of Revenue	-4.4%	47.00	50.00	58.00	85.00	103	104	108	132	115	100	106	100	92.00	66.00	67.00	61.00	43.00	43.00	47.00	46.00	41.00
Gross Profit	-10.0%	127	141	177	211	246	234	283	322	302	278	307	294	249	199	204	159	135	128	143	141	125
S&GA Expenses	-10.1%	119	133	152	172	193	201	235	273	247	231	252	232	196	161	159	131	112	109	123	113	100
EBITDA Margin	-15.5%	0.11*	0.13*	0.13*	0.13*	0.13*	0.12*	0.13*	0.13*	0.14*	0.15*	0.15*	0.16*	-	-	-	-	-	-	-	-	-
Income Taxes	-13.2%	3.00	4.00	3.00	9.00	13.00	6.00	12.00	10.00	13.00	13.00	13.00	14.00	12.00	10.00	10.00	6.00	5.00	-0.90	5.00	6.00	4.00
Earnings Before Taxes	18.2%	12.00	10.00	27.00	39.00	53.00	32.00	48.00	49.00	55.00	47.00	55.00	61.00	53.00	38.00	45.00	28.00	24.00	19.00	21.00	28.00	25.00
EBT Margin	-19.3%	0.10*	0.12*	0.12*	0.13*	0.12*	0.12*	0.12*	0.12*	0.14*	0.14*	0.15*	0.15*	-	-	-	-	-	-	-	-	-
Net Income	37.8%	8.00	6.00	23.00	30.00	40.00	27.00	36.00	39.00	42.00	34.00	42.00	47.00	41.00	28.00	34.00	22.00	18.00	20.00	16.00	21.00	21.00
Net Income Margin	-18.6%	0.08*	0.09*	0.10*	0.10*	0.09*	0.09*	0.09*	0.09*	0.10*	0.11*	0.11*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	-43.2%	5.00	10.00	28.00	41.00	62.00	43.00	54.00	41.00	41.00	-19.08	5.00	13.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.3%	303	310	320	319	322	316	326	341	421	398	371	364	326	276	261	232	202	195	199	213	210
Current Assets	-2.0%	220	224	224	229	230	223	230	243	324	307	301	304	282	234	217	191	161	154	158	172	169
Cash Equivalents	3.2%	97.00	94.00	113	147	124	88.00	70.00	61.00	118	104	155	192	206	164	156	131	91.00	77.00	81.00	96.00	102
Inventory	-15.2%	46.00	55.00	58.00	69.00	97.00	119	145	157	189	180	130	96.00	62.00	53.00	42.00	39.00	48.00	49.00	52.00	48.00	43.00
Net PPE	-0.9%	51.00	51.00	53.00	54.00	56.00	57.00	58.00	59.00	58.00	56.00	46.00	37.00	31.00	28.00	27.00	25.00	25.00	26.00	26.00	25.00	23.00
Liabilities	-15.3%	92.00	108	127	133	151	161	176	211	205	196	175	170	152	119	121	115	91.00	90.00	87.00	87.00	88.00
Current Liabilities	-16.4%	77.00	92.00	110	115	132	141	154	188	181	170	161	154	145	111	112	107	82.00	79.00	78.00	76.00	77.00
Shareholder's Equity	4.7%	211	201	193	186	171	155	151	129	216	202	196	195	175	157	140	117	111	105	111	126	122
Retained Earnings	4.8%	183	175	169	164	152	140	132	129	203	190	183	185	179	154	140	119	110	169	163	156	143
Additional Paid-In Capital	5.2%	28.00	27.00	24.00	22.00	19.00	22.00	19.00	-	13.00	12.00	13.00	11.00	9.00	8.00	5.00	3.00	0.00	-	12.00	11.00	10.00
Shares Outstanding	0.4%	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	12.00	12.00	12.00	12.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,000	-	-	-	2,000	-	-	-	3,300	-	-	-	1,500	-	-	-	1,500	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-30.8%	7,282	10,522	29,930	43,146	64,059	51,739	55,396	43,762	43,673	-7,459	15,800	20,878	65,326	19,829	41,114	57,518	26,735	19,152	17,897	14,478	32,734
Share Based Compensation	-9.3%	2,171	2,393	2,675	2,514	606	2,950	2,963	2,865	2,275	3,298	2,300	2,100	2,198	2,596	2,100	1,100	1,000	1,063	1,200	1,300	1,000
Cashflow From Investing	74.1%	-2,775	-10,731	-46,457	-1,744	-2,115	-9,064	-1,768	1,182	-1,764	-11,624	-10,389	-6,173	-878	570	-2,269	-289	706	-834	-952	-1,098	-3,444
Cashflow From Financing	91.7%	-1,491	-17,905	-18,153	-17,835	-25,896	-24,331	-45,106	-102,025	-28,119	-31,232	-42,945	-28,738	-22,218	-13,144	-13,186	-17,073	-13,741	-22,542	-32,058	-18,911	-8,813
Dividend Payments	-96.1%	710	17,978	18,043	17,833	19,163	17,922	18,081	18,957	16,660	17,011	16,750	16,703	13,392	13,298	13,324	13,314	13,254	8,738	8,909	8,923	8,826
Buy Backs	-	-	-	-	-	3,602	6,397	-	110,048	10,000	9,999	26,270	12,230	7,500	-	-	-	-	-	23,116	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MED Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 174,739	$ 348,983
Cost of sales	47,447	102,593
Gross profit	127,292	246,390
Selling, general, and administrative	119,352	192,879
Income from operations	7,940	53,511
Other income (expense)
Interest income (expense)	1,223	(181)
Other income (expense)	2,422	(1)
Total other expense	3,645	(182)
Income from operations before income taxes	11,585	53,329
Provision for income taxes	3,269	13,361
Net income	$ 8,316	$ 39,968
Earnings per share - basic (in usd per share)	$ 0.76	$ 3.68
Earnings per share - diluted (in usd per share)	$ 0.76	$ 3.67
Weighted average shares outstanding
Basic (in shares)	10,909	10,864
Diluted (in shares)	10,958	10,899
Cash dividends declared per share (in usd per share)	$ 0	$ 1.65

MED Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 97,471	$ 94,440
Inventories	46,273	54,591
Investments	58,957	55,601
Income taxes, prepaid	5,471	8,727
Prepaid expenses and other current assets	11,412	10,670
Total current assets	219,584	224,029
Property, plant and equipment - net of accumulated depreciation	50,986	51,467
Right-of-use assets	14,536	15,645
Other assets	13,648	14,650
Deferred tax assets	4,005	4,117
TOTAL ASSETS	302,759	309,908
Current Liabilities
Accounts payable and accrued expenses	71,229	86,415
Current lease obligations	5,958	5,885
Total current liabilities	77,187	92,300
Lease obligations, net of current lease obligations	14,611	16,127
Total liabilities	91,798	108,427
Stockholders' Equity
Common stock, par value $0.001 per share: 20,000 shares authorized; 10,937 and 10,896 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	11	11
Additional paid-in capital	27,963	26,573
Accumulated other comprehensive income	22	248
Retained earnings	182,965	174,649
Total stockholders' equity	210,961	201,481
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 302,759	$ 309,908

About Medifast Inc

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.

CEO	Mr. Daniel R. Chard
WEBSITE	https://medifastinc.com
INDUSTRY	Personal Services
EMPLOYEES	874

Medifast Inc Frequently Asked Questions

What is the ticker symbol for Medifast Inc? What does MED stand for in stocks?

MED is the stock ticker symbol of Medifast Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medifast Inc (MED)?

As of Wed May 15 2024, market cap of Medifast Inc is 277.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MED stock?

You can check MED's fair value in chart for subscribers.

What is the fair value of MED stock?

You can check MED's fair value in chart for subscribers. The fair value of Medifast Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Medifast Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Medifast Inc a good stock to buy?

The fair value guage provides a quick view whether MED is over valued or under valued. Whether Medifast Inc is cheap or expensive depends on the assumptions which impact Medifast Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MED.

What is Medifast Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, MED's PE ratio (Price to Earnings) is 4.09 and Price to Sales (PS) ratio is 0.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MED PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Medifast Inc's stock?

In the past 10 years, Medifast Inc has provided 0.005 (multiply by 100 for percentage) rate of return.